Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir

Overview of attention for article published in Drug & Therapeutics Bulletin, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#30 of 817)
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
twitter: 16 tweeters

facebook: 1 Facebook page

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 18 Mendeley

Summary News Twitter Facebook Dimensions citations

So far, Altmetric has seen 23 tweets from 16 users, with an upper bound of 128,293 followers.

Top 10 Thursday A countdown of the most accessed articles from 2022 4. Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir (DTB drug review) https://t.co/RR5nBVUdSY https://t.co/JSOCZYR67u

04 May 2023

Reply Retweet Favourite

And the answer is.... a. 0% Participants in the MOVe-OUT and EPIC-HR clinical trials for ▼molnupiravir and ▼nirmatrelvir + ritonavir had not been vaccinated against SARS-CoV-2. Exclusion criteria for both trials included SARS-CoV-2 vaccination. https://t

18 May 2022

Reply Retweet Favourite

RT @DTB_BMJ: DTB's overview of the covid-19 antivirals ▼molnupiravir and ▼nirmatrelvir + ritonavir is available free from our website. In t…

17 May 2022

Reply Retweet Favourite

RT @pash22: Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir https://t.co/IAo1qv8vSV via @DTB_BMJ @DrSi…

12 May 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 19 additional tweets.